--- title: "Absci raises $100 million at $7.41 a share" url: "https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-24" section: "Financings" tickers: "NASDAQ:ABSI" source: "https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering" summary: "The offering followed interim phase 1 data for ABS-201. Proceeds fund the antibody's hair loss and endometriosis programs." --- By the aibio.space Absci desk. Sources - [Absci](https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering) - [Absci Q2 2026 release](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) [ABSI](https://aibio.space/companies/absci/) 2026-06-24 # Absci raises $100 million at $7.41 a share with Eli Lilly among buyers Tickers [ABSI](https://aibio.space/companies/absci/) The offering followed interim phase 1 data for ABS-201. Proceeds fund the antibody's hair loss and endometriosis programs. ## Key facts - **Company**: Absci Corporation (NASDAQ: ABSI) - **News type**: Financings - **Primary source**: [Absci](https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering) *An empty boardroom with a long table. CC0, via rawpixel. The picture shows the field, not the companies named.* Absci priced an underwritten offering of [13,495,277 shares at $7.41 each](https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering) on June 24, 2026, raising about $100 million before fees. Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus and Redmile took part, along with an unnamed large investment management firm. Jefferies, J.P. Morgan, TD Cowen and Guggenheim Securities were joint book-running managers. The deal was expected to close on or about June 25, [the company said](https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering). Absci said it would use the money to advance ABS-201, its prolactin receptor antibody for pattern hair loss and endometriosis, and for working capital. ## The details Absci later reported $93.6 million in net proceeds from the offering, [in its second-quarter release](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial). The same release said Lilly made a $40 million strategic equity investment. The arrangement is tailored to ABS-201's clinical development strategy and gives Lilly no rights to the program. A Lilly representative joined Absci's endometriosis advisory board. The raise came on the same day Absci reported [interim phase 1 data](https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial) showing no serious adverse events in 32 healthy adults and an estimated half-life of at least 65 days for ABS-201. ## Context Before the deal, Absci had [$125.7 million in cash](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-first-quarter-2026-financial), cash equivalents and marketable securities at March 31, 2026, down from $144.3 million at the end of 2025, and guided to runway into the first half of 2028. It lost $29.6 million in the first quarter. After the raise, cash stood at [$201.1 million at June 30](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) and runway guidance moved to the second half of 2028. The offering price was above the level of early May. Absci set the exercise price of a [May 1 inducement option](https://investors.absci.com/news-releases/news-release-details/absci-announces-inducement-grant-under-nasdaq-listing-rule-2) at $4.92, the Nasdaq closing price that day. In May the company said it expected to sign one or more partnerships in 2026, including one with a large drugmaker, [per its first-quarter release](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-first-quarter-2026-financial). ## What it means for investors Absci raised money after clean early safety data, at a price above the $4.92 close of May 1, for a company with one clinical asset. The named buyers include several dedicated biotech investors, and the Lilly check adds a strategic name. The terms deserve a close read. Lilly gets no rights, so the investment does not lock in a partner. Absci's own guidance for a large pharma partnership in 2026 has not yet been met in its public releases. The new shares also add about 13.5 million to the count, and every later raise before a product reaches market will add more. The bet behind the raise is that ABS-201 shows hair regrowth in people with pattern hair loss. Phase 1 drugs reach approval only [7.9% of the time](https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf) on published base rates. ## What to watch Absci reports third-quarter results on [Nov. 12, 2026](https://investors.absci.com/news-releases/news-release-details/absci-report-business-updates-and-third-quarter-2026-financial). Interim hair loss proof-of-concept data are due in the second half of 2026, and full data in early 2027. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ABSI Absci Corporation NASDAQ ยท United States Open the desk ## More from the Absci desk Financings ### [Absci cash rises to $201 million after June raise; Lilly invests $40 million](https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/) Aug 11, 2026 Mergers ### [Absci and Totient sellers agree final milestone payout under 2021 merger agreement](https://aibio.space/news/absci-totient-sellers-agree-final-milestone-payout-under-2021-merger/) Nov 4, 2025 Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 --- Source page: https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Absci raises $100 million at $7.41 a share", 2026-06-24, https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/